Peritoneal Cancer – Pipeline Review, H2 2018

Peritoneal Cancer – Pipeline Review, H2 2018


Peritoneal Cancer – Pipeline Review, H2 2018, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Peritoneal Cancer – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 14, 78, 52, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
3-V Biosciences Inc
AbbVie Inc
Advenchen Laboratories LLC
AiVita Biomedical Inc
Aldeyra Therapeutics Inc
Altor BioScience Corp
ALX Oncology Inc
Amgen Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Atara Biotherapeutics Inc
Bayer AG
BeiGene Ltd
Biocon Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Co
Celgene Corp
Celsion Corp
CerRx Inc
Chipscreen Biosciences Ltd
Clovis Oncology Inc
Corcept Therapeutics Inc
Cotinga Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Eli Lilly and Co
EpiThany Inc
Epizyme Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Forty Seven Inc
Gene Techno Science Co Ltd
Genelux Corp
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Hemispherx Biopharma Inc
ImmunoGen Inc
Innate Pharma SA
InSight Biopharmaceuticals Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kyowa Hakko Kirin Co Ltd
Lidds AB
MabVax Therapeutics Holdings Inc
Mateon Therapeutics Inc
MaxCyte Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mersana Therapeutics Inc
Millennium Pharmaceuticals Inc
Morphotek Inc
Morvus Technology Ltd
Mycenax Biotech Inc
NewLink Genetics Corp
Novartis AG
NuCana Plc
Oasmia Pharmaceutical AB
OBI Pharma Inc
Oncobiologics Inc
Oncoinvent AS
Oncolix Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
Plexxikon Inc
Polaris Pharmaceuticals Inc
Prescient Therapeutics Ltd
Protheragen Inc
PsiOxus Therapeutics Ltd
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Rgenix Inc
Rigel Pharmaceuticals Inc
Samyang Holdings Corp
Sanofi Pasteur SA
SELLAS Life Sciences Group Inc
Soricimed Biopharma Inc
Sotio AS
Sun Pharma Advanced Research Company Ltd
Syndax Pharmaceuticals Inc
Synermore Biologics Co Ltd
Targovax ASA
Tyrogenex Inc (Inactive)
Vascular Biogenics Ltd
Verastem Inc
Vyriad Inc

For queries regarding this report:

Contact Us:
Sales Desk
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets, a leading Market Research Reports Reseller trusted by Fortune listed companies for their requirements of Syndicated and Custom Market Research Reports. Ritesh has an overall experience of 18+ years in Recruitments, Sales and Operations. He has been associated with the Market Research industry for the past 7 years. He is an avid foodie as well as a huge football fan being a supporter of Manchester United (EPL) and FC Barcelona (La Liga). Get in touch with him via *Market Research News is a part of Research By Markets.